

Targeting T Cells in Cancer Immunotherapy


Alexey Chiron*

Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran

Abstract

Cancer immunotherapy has emerged as a revolutionary approach in the battle against cancer, focusing on harnessing the body's immune system to target and destroy malignant cells. T cells, a critical component of the immune system, play a central role in this therapeutic strategy. This abstract provides a concise overview of the state-of-the-art in Targeting T Cellsng .e sta96ivlutg6ivlutgi176(tdlia41.9)-0W n scn/CS es i9ei22idT\(\mathbf{s}\) w0r2id6m29(naib and dg on o7ti)y 0 cs 0 0.4m

groundbreaking approach in cancer immunotherapy is Chimeric Antigen Receptor (CAR) T cell therapy. CAR T cells are T cells that are genetically engineered to express a receptor specic to a cancer-associated antigen. Once infused back into the patient's body, these CAR T cells seek out and destroy cancer cells bearing the targeted antigen, oering highly targeted treatment with minimal harm to healthy tissue §



*Corresponding author:

Citation: Chiron A (2023) Targeting T Cells in Cancer Immunotherapy. Immunol Curr Res, 7: 174.

